

1 **Within-host density and duration of colonization of** 2 **multidrug-resistant Enterobacterales acquired during** 3 **travel to the tropics**

4
5 Olivier Cotto^{1,3}, Laurence Armand-Lefèvre², Sophie Matheron², Etienne Ruppé², François

6 Blanquart^{1#}, on behalf of the VOYAG-R study group*

7
8 1. Centre for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS,

9 INSERM, PSL Research University, Paris, France

10
11 2. Université de Paris, IAME, INSERM, 75018, Paris, France

12 AP-HP, Hôpital Bichat, Laboratoire de Bactériologie, Hôpital Bichat-Claude Bernard, 46 rue

13 Henri Huchard, 75018, Paris, France

14
15 3. PHIM Plant Health Institute Montpellier, University of Montpellier, INRAE, CIRAD,

16 Institut Agro, IRD, CEDEX 5, 34398 Montpellier, France

17
18 *The VOYAG-R study group: Antoine Andreumont, Laurence Armand-Lefèvre, Olivier

19 Bouchaud, Yacine Boussadia, Pauline Campa, Bruno Coignard, Paul-Henri Consigny, Assiya

20 El Mniai, Marina Esposito-Farèse, Candice Estellat, Pierre-Marie Girard, Catherine Goujon,

21 Isabelle Hoffmann, Guillaume Le Loup, Jean-Christophe Lucet, Sophie Matheron, Nabila

22 Moussa, Marion Perrier, Gilles Pialoux, Pascal Ralaimazava, Etienne Ruppé, Daniel Vittecoq,

23 Ingrid Wieder and Benjamin Wyplosz.

24
25 # Contact author: francois.blanquart@college-de-france.fr

26

27 **Abstract (149 words):**

28 Although it seems obvious that antibiotic use promotes antibiotic resistance, the processes
29 underlying the changes in prevalence of MRE in European communities are still poorly
30 understood. Information on how the within-host bacterial density varies after acquisition of a
31 resistant strain and in the absence of antibiotic selection is key to our ability to further
32 understand, model and manage resistance in the community. Empirical studies on the within-
33 host dynamics following colonization by MRE are very scarce. Here, we study the within-host
34 strain dynamics in healthy travelers colonized with MRE upon their return from tropical
35 regions. Densities of both sensitive and resistant strains are stable for a few months, until
36 resistant strains are abruptly cleared. Multivariate survival analysis further revealed that MRE
37 acquired from Asia and carried at larger densities persist for longer. These dynamics do not
38 support the classically assumed slow competitive exclusion of MRE. Rather, MRE and
39 sensitive strains coexist in apparent equilibrium for months, with MRE representing about
40 0.1% of total Enterobacterales, before MRE are abruptly cleared. These results inform
41 potential therapeutic strategies to clear MRE and epidemiological models of antibiotic
42 resistance.

43

44 **Key words:** Escherichia coli, antibiotic resistance, prevalence, epidemiology, intra-host
45 dynamics, cost of resistance.

46

47 **Running title:** Within-host dynamics of resistant *E. coli*

48

49 Introduction

50 Multidrug-resistant Enterobacterales (MRE) pose major public health issues. Common types of
51 MRE include Enterobacterales (EB) producing extended-spectrum β -lactamase (ESBL),
52 plasmid encoded AmpC-type cephalosporinase and/or carbapenemase. ESBL-producing
53 *Escherichia coli* strains represent the largest fraction of MRE in the community [1,2]. MRE can
54 degrade most β -lactam antibiotics, which limits treatment alternatives in the cases of infection.
55 The prevalence of MRE in developed countries has increased in the last two decades [2,3], but
56 seems to have stabilized at 5-15% prevalence since around 2010 in some European countries
57 [4,5]. Although it seems obvious that antibiotic use promotes antibiotic resistance, the processes
58 underlying the changes in prevalence of MRE in European communities are still poorly
59 understood [6,7].

60 Information on how the within-host bacterial density varies after acquisition of a
61 resistant strain and in the absence of antibiotic selection is key to our ability to further
62 understand, model and manage resistance in the community. Indeed, within-host dynamics
63 determine the shedding of the resistant strain and potential onward transmission [8].
64 Understanding within-host dynamics can also guide the design of strategies to eliminate
65 resistant strains. For example, the elimination of MRE strains by competition with ingested
66 sensitive strains is envisioned to limit resistance in farm animals [9] and humans [10]. At the
67 epidemiological level, recent mathematical modelling suggests that the emerging
68 epidemiological dynamics of resistant and sensitive strains in the community and the
69 equilibrium frequency of resistance critically depend on within-host dynamics [11]. Precisely,
70 long-term coexistence of resistant and sensitive strains within the host after treatment could
71 help maintain a moderate stable prevalence of MRE at the population scale. This result relies
72 on the slow dynamics of competitive exclusion of the resistant strain by a sensitive strain in
73 untreated hosts, occurring over several months.

74 Very few studies provide insights on the patterns of within host dynamics of resistant
75 and sensitive strains *in vivo*. Indeed, longitudinal surveys of strain density during and after
76 antibiotic treatment are challenging to implement. An experimental study of 20 piglets under
77 5-days ciprofloxacin treatment showed that the density of resistant strains increased over the
78 course of treatment and shortly after (days 0-7), then briefly declined (days 7-12), presumably
79 because of the competition with sensitive strains; from day 12 onward to day 27, no decline in
80 the density of resistant strains was noticeable: they remained at a detectable density of
81 approximately 1% of total Enterobacteriaceae [12]. A study of 133 patients longitudinally
82 followed during hospital stays (lasting 15 days on average) evidenced a clear signal of selection
83 for bacteria carrying CTX-M enzymes during 3rd generation cephalosporin treatment. The study
84 suggested that resistant strains are then slowly outcompeted by sensitive strains over relatively
85 short time scales of 30 days [13]. However, in that study it is not clear what is the strength of
86 the evidence for the declining density of resistant strains after treatment; the absolute value of
87 the extinction threshold is tuned to match the median time to extinction of 30 days inferred in
88 a separate study of returning travellers [8]; and the individual trajectories of resistance density
89 in the 19 untreated individuals did not present a decline (Figure 1 right panel in [13]). We will
90 come back to this study in more details and in comparison with our results in the discussion. To
91 date, no other study investigated the change in resistant strain density until clearance in
92 untreated hosts. More data analyses are required for further understanding of the within-host
93 dynamics of resistant strains, especially over longer time scales and in healthy subjects.

94 In the present study, we take advantage of data from a previously published monthly
95 survey of both total EB and MRE density in a cohort of healthy travelers returned from tropical
96 regions with MRE carriage [14]. Previous analyses of these data showed that, at the population
97 level, short MRE carriage was associated with low MRE density relative to the total EB density.
98 At the individual scale, the within-host dynamics of MRE density following travel has,

99 however, not been investigated. In particular, the rate of decline of the density of resistant
100 strains and the distribution of the time to clearance of these strains after return from travel has
101 not been described.

102 Here, to get insights on the within-host MRE dynamics, we extend previous analyses
103 from Ruppé et al. [14] by focusing on MRE dynamics at the individual level. We investigate
104 both the dynamics of MRE density and the dynamics of total EB, from which we can deduce
105 the density of sensitive EB strains. We discuss the implications of these results for our
106 understanding of the mechanisms driving the within-host dynamics of resistant and sensitive
107 strains after treatment, for the development of between-host models of resistance evolution, and
108 for new approaches to eliminate MRE from the gut with probiotics.

109 **Methods**

110 **Description of the study**

111 Healthy individuals planning to travel to the three main tropical regions (sub-Saharan Africa,
112 Latin America including the Caribbean, and Asia) volunteered to complete a basic
113 questionnaire, provide a stool sample prior to travel and regular stool samples after their return.
114 These samples were used to verify that no MRE was carried before travel and monitor the
115 presence of MRE and the density of MRE over time after travel [14]. The questionnaire
116 included information on malaria prophylaxis with doxycycline and the type of antibiotic used
117 during travel, if any.

118 Only individuals who did not carry MRE before travel were included in the study.
119 Participating individuals then provided a stool sample within a week after their return from
120 travel. All samples were screened for MRE. The 292 individuals who were carrying MRE at
121 return were asked to provide samples 1, 2, 3, 6 and 12 months later or until no MRE were
122 detected. Individuals who did not carry MRE at return were not considered for follow up. For
123 each stool sample, the total density of EB and the density of MRE (in CFU/mL) were quantified

124 at reception of the samples. In parallel, an enrichment step allowed to detect whether MRE
125 occurred at very low density [14]. Colony-forming units were all tested and were considered
126 to be the same clone when they were of the same species, had the same morphotype and had
127 the same antibiotic resistance profile. EB species were not identified, but most of the MRE were
128 *E. coli* (93.3 %, see [15]). The details of the analysis of the stool samples can be found in Ruppé
129 et al. [14]. Importantly, MRE were searched on fresh stool samples (not rectal swabs, self-
130 collected at the traveler's home and promptly shipped to the bacteriology laboratory of Bichat-
131 Claude Bernard Hospital in Paris, France) using enrichment steps which increased the
132 sensitivity for MRE detection [15]. This enabled detection of MRE at a density above 1000
133 CFU/mL. The details of the microbiological processing of the samples can be found in Ruppé
134 et al. [14].

135 Previous analyses identified the factors associated with MRE acquisition in this cohort
136 of travelers. In particular, the region of travel and the use of β -lactam antibiotics during travel
137 had the strongest effects on the probability to carry MRE after return [14]. Here, we extend the
138 investigation to the within-host dynamics of MRE density in a six-month period following
139 return from travel. To this aim, we analyzed the density of both EB and MRE as a function of
140 time for each individual in the survey and conducted a survival analysis of MRE strains
141 following travel.

142 **Statistics**

143 All analyses were performed using the software R [16]. The density data were \log_{10} -
144 transformed. We visually verified that the transformed densities followed approximately a
145 normal distribution. The relative MRE density was defined as the difference between the total
146 log-density of EB and the log-density of MRE. The analyses were performed on the subset of
147 224 (among 292) individuals who acquired MRE during travel, who pursued the study until no
148 MRE were detected in their stools (i.e. not lost to follow up), and for whom the MRE carried

149 were *E. coli*. In total, the analyses were conducted on 353 samples (224, 64, 36, 18, 8, 3 at each
150 sampling time – see above, respectively). A flowchart of the survey is provided in Figure 1 of
151 [14]. The details of the statistical analysis are available in Supplementary Material as a R-
152 markdown document.

153 Among the 224 individuals who acquired MRE during travel and who were kept in the
154 analysis, 108 traveled to Asia, 70 to Africa, and 46 to America. A total of 60 individuals used
155 antibiotics during travel (26 in Asia, 22 in Africa and 12 in America). Four types of antibiotics
156 were used: doxycycline (here used for malaria prophylaxis only), nifuroxazide, β -lactam and
157 fluoroquinolone. Preliminary statistical analyses showed that doxycycline and nifuroxazide did
158 not have an effect on the density of MRE (see Supp. Mat.). These antibiotics were excluded
159 from the remaining analysis. For simplicity, further use of the denomination antibiotics will
160 refer to both β -lactam and fluoroquinolone.

161 First we investigated the change in density of EB and MRE over time using mixed linear
162 models with individual identity as a random effect on the intercept (R-package lme4, [17]). We
163 did not have enough data points to support models with an individual random effect on the
164 slope. All the analyses were multivariate. Model selection was performed by first constructing
165 the full model, with all potentially relevant explaining variables, and then building all possible
166 nested models. The AIC criterion was used to select the best (i.e., most parsimonious) model
167 where likelihood ratio tests were performed to obtain p-values associated with the remaining
168 explaining variables.

169 Second, we used standard survival analyses (R-package survival, [18]) to investigate
170 the rate of MRE clearance as a function of time since return from travel. We conducted both
171 semi-parametric (Cox-models, Appendix 1) and parametric analyses. We fitted fully parametric
172 models of clearance separately for each travel region with relative MRE density and the use of
173 antibiotics during travel as explanatory variables. Therefore, the best model for each region

174 reflects the persistence of the MRE strains acquired in this region and its dependence on MRE
175 density and use of antibiotics. For parametric models, we compared an exponential hazard
176 model, which assume that the instantaneous clearance hazard does not vary with time, with
177 models of changing clearance rate with time such as the Weibull model and the log-logistic
178 model. Parametric models provide full information on clearance rate as a function of time,
179 contrary to semi-parametric (Cox) models.

180 Results

181 Density of MRE as a function of time

182 Our main result is that the within-host density of MRE did not vary with time after return from
183 travel (Figure 1). Indeed, we did not find evidence that the density of MRE (conditional on
184 MRE carriage) change with time after travel ($\beta_{time} = 0.0509 [-0.067 ; 0.17]$ CFU/mL per
185 month, $\chi^2_{df=1} = 0.78$, $N = 353$, $p = .37$, Figure 1). To investigate whether this result holds even
186 for the subset of short-term MRE carriers, we further restricted the analysis to the hosts who
187 cleared their MRE in the second month after their return (the mean half-time before clearance
188 is between 1 and 2.5 months depending on the travel region, see below). These hosts provided
189 two samples containing MRE, within a week after return and one month after return. In these
190 short-term carriers, we also found that both absolute ($\beta_{time} = -0.18 [-0.91 ; 0.54]$ CFU/mL per
191 month, $\chi^2_{df=1} = 0.26$, $N = 56$, $p = .61$) and relative MRE density ($\beta_{time} = -0.22 [-1.03 ; 0.579]$
192 CFU/mL per month, $\chi^2_{df=1} = 0.33$, $N = 56$, $p = .57$) did not change significantly with time. In
193 other words, in short-term carriers, MRE density did not vary during the first month, and MRE
194 was cleared during the second month after return.

195 With a simulation study, we verified the power of our analysis to detect a within-host
196 decline in MRE density and the accuracy of parameter inference. In this study we used the
197 between-host variance and error parameters inferred from the linear model (Supplementary
198 Figure S1). We found that the size of our data set and the level of error in density measures


199 were sufficient to ensure a 100% power to detect a decline in density and a good accuracy of
200 parameter estimates for relevant values of the within-host decline. The power dropped to 50%
201 only for very slow declines in density of -0.1 per month: this slow decline would imply that
202 MRE density falls to undetectable values on average after more than four years.

203 We further found in our data that the density of MRE increased with the number of
204 distinct MRE strains ($\chi_{df=1}^2 = 11.4$, $N = 353$, $p = .0007$, $\beta_{nb.strains} = +0.29$ [0.10 ; 0.42] \log_{10}
205 CFU/mL per strain). The mean number of MRE strains upon return was 1.8 (median: 1 [1-8]).
206 Moreover, consistent with previous results, we found that the travel region ($\chi_{df=2}^2 = 7.4$, $N =$
207 353 , $p = .025$) and the use of antibiotics ($\chi_{df=1}^2 = 11.4$, $N = 353$, $p = .0007$) contributed to the
208 variation in MRE density. In particular, travelers returning from Asia had a larger density of
209 MRE than travelers returning from other regions ($\beta_{Asia} = 0.63$ [0.19 ; 1.09] \log_{10} CFU/mL and
210 Figure 1) and travelers exposed to antibiotics had a larger density of MRE than those who were
211 not ($\beta_{atb} = 1.19$ [0.41 ; 1.72] \log_{10} CFU/mL, and Figure 1).

212 For the total EB density, we found that the null model (with the intercept only)
213 performed best, such that none of the potential explaining factors significantly contributed to
214 the observed variation (Figure 1). Consequently, the factors contributing to the variation in
215 relative MRE density are similar to those explaining the variation in absolute MRE density (as
216 presented above, see Supp. Mat.).

217 Among all EB carried by an individual, only a small fraction of cells was resistant. For
218 each sample, we compared the likelihood of a model assuming that the total number of EB and
219 MRE per sample followed different Poisson distributions with that of a model assuming that
220 both numbers per sample followed the same Poisson distribution. In all cases, the best model
221 suggested total EB density was significantly larger than MRE density ($\Delta AIC \gg 2$). On average,
222 MRE represented 0.1% of the total EB population (Figure 1).

223



224

225 Figure 1: Density of bacteria as a function of time. Red and black correspond to MRE and EB
226 densities respectively. Individual time-trajectories in bacterial densities are represented in light
227 hue. Dots at the end of an individual MRE trajectory materialize the last time MRE were
228 detected (single dots correspond to individuals who cleared their MRE during the first month).
229 Thick solid lines represent linear model predictions and dashed lines represent the 95% C.I. A,
230 B and C: individuals returned from each of the three travel regions. D and E, individuals who
231 did and did not use antibiotics during travel, respectively. F: Mean densities as a function of
232 time. Log is on base 10.

233

234 Clearance rate of MRE strains after travel

235 Even though the density of MRE did not vary with time, the proportion of individuals carrying
236 MRE decreased with time as MRE were cleared. We characterized the instantaneous clearance
237 rate of MRE as a function of time. Preliminary Cox survival analyses (Appendix 1) indicated
238 that both the use of antibiotics and the relative density of MRE had an effect on the clearance

239 rate, but not the number of MRE strains carried. However, since the proportional hazard
240 hypothesis was not met for the region of travel (Supp. Mat), we develop below our main
241 analysis based on parametric models.


242 With parametric models, we found that log-logistic clearance models best described
243 MRE clearance as a function of time (Figure 2). The instantaneous clearance rate was unimodal,
244 first increasing with time to reach a maximum, and then decreasing (scale parameter < 1). The
245 peak clearance rate occurred at about 2.5, 1.5 and 1.7 months for traveler from Asia, Africa and
246 America respectively. Overall, the log-logistic models fitted well the pattern of MRE clearance
247 in the first three months after travel (especially for Asia), but failed to capture MRE persistence
248 later on (Figure 2).

249 MRE carried at large relative density persisted for longer. The effect of relative MRE
250 density was strongest in travelers returning from Asia (a factor 1.18 [1.10-1.26] per \log_{10} CFU)
251 followed by Africa (1.04 [1.01-1.09] per \log_{10} CFU) and Latin America (1.02[0.93-1.10] per
252 \log_{10} CFU).

253 The effects of the antibiotic treatment on the persistence of MRE strains depended on
254 the travel region (see details in Supp. Mat.): the use of antibiotics during travel decreased the
255 persistence time of MRE strains (after return) by a factor 0.59 [0.39-0.88] in travelers from
256 Asia, but increased it by a factor 2.73 [1.51-4.95] and 1.59 [1.08-2.33] in travelers from Latin
257 America and Africa, respectively.

258 According to the survival models, the half-life (time at which 50% of individuals have
259 cleared MRE) was 2.47, 1.17 and 1.24 months in travelers returning from Asia, Africa, and
260 America respectively, when carried at the median relative density. The equivalent figures for
261 MRE carried at the lower 5% density were 1.5, 1.17 and 1.24 months in travelers returning from
262 Asia, Africa and America respectively. For MRE carried at the higher 95% density, they were
263 3.64, 1.36 and 1.34 months.

264



265

266 Figure 2: survival curves of MRE strains acquired in the different regions. Solid lines: Kaplan-
267 Meier survival curves from the data; dashed lines: predictions from the log-logistic model. For
268 the sake of illustration, the models include only the effect of the relative MRE density as a
269 covariate. The effect of the use of antibiotics during travel are shown in Fig. S2.

270 Discussion

271 Our study provides new insights on the within-host dynamics of travel-acquired MRE in the
272 gut. Our first main result is that clearance occurs abruptly after a period of stable MRE density
273 that can last several months (Figure 1 and Figure 3 scenario 1). This scenario contrasts with the
274 classical expectation that clearance is the end-result of a slow process of competitive exclusion
275 (Figure 3, scenario 2). Our second main result lies in the detailed characterization of MRE
276 clearance as a function of time, travel region and within-host density. This reveals distinct
277 dynamics for strains from different regions, MRE from Asia being the most persistent, and an
278 effect of MRE density on persistence.

279 The mechanisms associated with MRE clearance are not known. We found that the
280 clearance rate of MRE decreased with their density, suggesting that density-dependent

281 mechanisms are involved in MRE clearance. Competitive exclusion of resistant strains by
282 sensitive ones has been proposed as a candidate mechanism [11]. Indeed, resistance
283 mechanisms often induce a fitness cost, which decrease competitiveness in the absence of
284 antibiotics [19]. Our results are not in contradiction with this view, but we showed that if
285 competitive exclusion does occur, its effect on MRE strain density and the eventual clearance
286 can occur as a brief event after a relatively long period of stable coexistence between resistant
287 and sensitive strains.

288 How do our results compare to previous evidence? As explained in the introduction, the
289 best previous study on longitudinally followed-up hospitalized individuals clearly demonstrates
290 antibiotic selection on CTX-M-carrying bacteria, but does not give much details on the strength
291 of the evidence for a decline in resistant strain density after treatment, and on the absolute value
292 of this decline [13]. In an effort to understand this decline in greater details, we re-analyzed the
293 dynamics of resistance in these data, focusing on never-treated individuals (N=19) and on
294 treated individuals in untreated periods (N=51). We further stratified untreated periods into
295 periods following 3rd generation cephalosporin treatment (ceftriaxone, cefuroxime: C3G) or
296 other treatments (Supplementary Figure S2). We found no decline of resistance in never-treated
297 individuals (linear model, $\beta_{time} = -0.0015$ per day $[-0.037, 0.034]$, $p = 0.93$), nor in
298 individuals treated with non-C3G treatment (linear model, $\beta_{time} = 0.00033$ per day
299 $[-0.041, 0.042]$, $p = 0.99$). However, after C3G treatment, the density of resistance was
300 elevated and there was evidence for a decline in density in the first few days post-treatment
301 (linear model, $\beta_{time} = -0.14$ per day $[-0.19, -0.088]$, $p = 2.6 \cdot 10^{-7}$). These results from
302 hospitalized individuals under C3G treatment are thus fully consistent with experimental results
303 on piglets under ciprofloxacin treatment [12] and with our own results. Together this suggests
304 biphasic dynamics of resistance post-treatment: first, over a few days, a rapid decline in
305 resistance density as the sensitive strains re-establish and grow; second, over a few weeks to

306 months, a stable equilibrium at which resistant strains persist at a small fraction of total density,
307 before being eventually cleared.

308 We propose two mechanisms of note that could result in these clearance dynamics.
309 Clearance may be caused either by the coexisting sensitive strains, or by displacement by new
310 incoming sensitive strains. The first mechanism would require threshold effects on strain
311 dynamics, as observed in other systems [20,21], to explain the sudden clearance after weeks or
312 months of stability. The second mechanism requires that some combinations of strains stably
313 coexist within hosts, but other incoming strains might very quickly disrupt the equilibrium. In
314 any case, the coexistence over several months of resistant and sensitive strains, without change
315 in density, poses the question of the mechanisms permitting the persistence of resistant strains
316 despite their much lower density reflecting a fitness cost. This is a significant resistant
317 subpopulation: 0.1% of the total density of Enterobacterales implies of the order of 100 millions
318 resistant cells persisting in the gut for extended periods of time in apparent equilibrium with the
319 sensitive strains, in spite of their cost. Resistance genes could be associated with genes
320 enhancing persistence [22], increasing the mean time before colonization by a competing
321 sensitive strain. Further research is needed to understand this intriguing long-term strain
322 coexistence and the mechanisms of strain replacement.


323 Density-dependent mechanisms leading to MRE clearance could also occur at the scale
324 of Enterobacterales species other than *E. coli*, or other members of the microbiota. Most (>
325 90%) MRE were identified as *E. coli*. Total Enterobacterales (the vast majority of which were
326 sensitive) were not identified at the species level. In a similar protocol investigating stool
327 samples of healthy individuals, *E. coli* account for around two thirds of total Enterobacterales.
328 Moreover, a study from our group reported that a rapid MRE clearance (within one month after
329 return) was associated with a high relative abundance of *Bifidobacterium* spp. and bacteria

330 from the Clostridiales order in the gut [23]. Regardless of whether competition occurs at the
331 intra- or interspecific scale, clearance is an abrupt process without prior decline in density.

332 The simulation study indicated that our longitudinal design had a 100% power to detect
333 plausible fast and slow declines in MRE density, and good accuracy to estimate this decline. Of
334 course, clearance must be preceded by a decline in MRE density, although the timescale of this
335 decline was too fast to be observed. The analysis of MRE density focusing on the subset of
336 travelers who lost their MRE between the first and second month indicates that density did not
337 change during the first month, consistent with the overall analysis and suggesting the timescale
338 of the decline is much faster than one month. Lastly, we did not have information on the use of
339 antibiotics or health care after return from travel. Travelers following the survey were healthy,
340 and the average rate of antibiotic consumption in the adult population low [24]. We expect that
341 the use of antibiotics during the survey was sufficiently rare not to affect our overall
342 conclusions.

343 Our survival analysis showed that the clearance rate is best described by log-logistic
344 functions of time, with parameters depending on the travel area, on the density of MRE, and on
345 whether travelers used antibiotics. Log-logistic clearance rates implies that the clearance rate
346 increased with time to reach a peak before decreasing. The peak probability of clearance
347 occurred between one and three months after return from travel, consistent with previous
348 estimates of median MRE carriage time [14]. The variation of the clearance rate with time could
349 reflect the diversity of MRE strains acquired during travel. Genomic analyses the 11 long-term
350 carriers from the present data set showed that MRE strains vary in their persistence ability, with
351 a single strain responsible of all carriage time exceeding three months [22]. At the population
352 level, a diversity of MRE strains with variable persistence ability can result in an unimodal
353 clearance rate as a function of time. The longer persistence of MRE acquired in Asia could be
354 explained if persistent MRE strains are more likely to circulate in Asia than in other regions.

355 The timescale of MRE clearance has several implications. First, it informs the structure
356 of mathematical models which aim to explain MRE prevalence at the community level. For
357 example, Davies et al. [11] modeled a succession of states corresponding to a slow (several
358 months) competitive replacement of resistant by sensitive strains. Our analysis shows that
359 modeling competitive replacement as a slow process may not be appropriate. Second, ingested
360 probiotics have been recently proposed to competitively replace MRE strains in the gut [10].
361 This strategy has further received some support from preliminary assessments in chickens
362 [9,25]. Our results suggest that competitive exclusion by probiotic might occur in one or two
363 ways. Along the first mechanism, competition between strains results in a period of stability
364 over several months, followed by rapid clearance. Along the second mechanism, some
365 combinations of MRE strains and probiotic strains would not result in clearance of MRE strains,
366 while others would be highly effective and rapidly clear MRE. It would thus be important to
367 distinguish between the two mechanisms. In future work, one way to do so would be to follow
368 the within-host dynamics of *both* MRE and sensitive strains to model jointly their dynamics
369 and turnover rates. We expect that our results will be of interest for future analyses of the role
370 of competition to exclude MRE from the gut and for the development of models to understand
371 and predict variation in MRE prevalence at the community level.
372



373

374 Figure 3: Alternative scenarios of MRE clearance. Left panel: after return from travel, MRE
375 are slowly outcompeted by sensitive strains, until the density of MRE falls below the detection
376 threshold. Right panel: The density of MRE at return from travel does not change with time,
377 but MRE are eventually cleared. Our results favor this second scenario.

378

379

380 **Acknowledgements**

381 **Conflict of interest**

382 The authors declare no conflict of interest.

383

384 **Funding**

385 OC and FB were founded by a CNRS momentum grant to FB. F.B. is funded by the ERC StG
386 949208 EvoComBac.

387

388 **Ethical Statement**

389 The VOYAG-R study was approved by the Ile de France IV ethics committee on 14
390 November 2011. The study was observational and did not directly benefit the participants.
391 French law requires that each participant sign a “nonrefusal” form. When MRE (including
392 CPE) carriage was detected, the individual concerned was sent an information leaflet on MRE
393 carriage, basic hygiene, and the need to mention this carriage when receiving medical care.
394 Individuals with CPE carriage received a similar leaflet and were also contacted by the
395 infection control practitioner of Bichat-Claude Bernard Hospital to ensure the information
396 was correctly understood.

397


398 References

- 399 1. Birgy A, Cohen R, Levy C, Bidet P, Courroux C, Benani M, Thollot F, Bingen E.
400 2012 Community faecal carriage of extended-spectrum beta-lactamase-producing
401 Enterobacteriaceae in French children. *BMC Infect. Dis.* **12**, 1–5.
- 402 2. Woerther P-L, Burdet C, Chachaty E, Andremont A. 2013 Trends in human fecal
403 carriage of extended-spectrum β -lactamases in the community: toward the globalization of
404 CTX-M. *Clin. Microbiol. Rev.* **26**, 744–758.
- 405 3. Gagliotti C *et al.* 2011 Escherichia coli and Staphylococcus aureus: bad news and
406 good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net,
407 formerly EARSS), 2002 to 2009. *Eurosurveillance* **16**, 19819.
- 408 4. Birgy A, Levy C, Bidet P, Thollot F, Derkx V, Béchet S, Mariani-Kurkdjian P, Cohen
409 R, Bonacorsi S. 2016 ESBL-producing Escherichia coli ST131 versus non-ST131: evolution
410 and risk factors of carriage among French children in the community between 2010 and 2015.
411 *J. Antimicrob. Chemother.* **71**, 2949–2956.
- 412 5. Blanquart F. 2019 Evolutionary epidemiology models to predict the dynamics of
413 antibiotic resistance. *Evol. Appl.* **12**, 365–383.
- 414 6. Colijn C, Cohen T, Fraser C, Hanage W, Goldstein E, Givon-Lavi N, Dagan R,
415 Lipsitch M. 2010 What is the mechanism for persistent coexistence of drug-susceptible and
416 drug-resistant strains of Streptococcus pneumoniae? *J. R. Soc. Interface* **7**, 905–919.
- 417 7. Lipsitch M, Colijn C, Cohen T, Hanage WP, Fraser C. 2009 No coexistence for free:
418 neutral null models for multistrain pathogens. *Epidemics* **1**, 2–13.
- 419 8. Arcilla MS *et al.* 2017 Import and spread of extended-spectrum β -lactamase-
420 producing Enterobacteriaceae by international travellers (COMBAT study): a prospective,
421 multicentre cohort study. *Lancet Infect. Dis.* **17**, 78–85.
- 422 9. Ceccarelli D, van Essen-Zandbergen A, Smid B, Veldman KT, Boender GJ, Fischer
423 EA, Mevius DJ, van der Goot JA. 2017 Competitive exclusion reduces transmission and
424 excretion of extended-spectrum- β -lactamase-producing Escherichia coli in broilers. *Appl.*
425 *Environ. Microbiol.* **83**, e03439-16.
- 426 10. Ljungquist O, Kampmann C, Resman F, Riesbeck K, Tham J. 2020 Probiotics for
427 intestinal decolonization of ESBL-producing Enterobacteriaceae: a randomized, placebo-
428 controlled clinical trial. *Clin. Microbiol. Infect.* **26**, 456–462.
- 429 11. Davies NG, Flasche S, Jit M, Atkins KE. 2019 Within-host dynamics shape antibiotic
430 resistance in commensal bacteria. *Nat. Ecol. Evol.* **3**, 440–449.
- 431 12. Nguyen TT, Guedj J, Chachaty E, de Gunzburg J, Andremont A, Mentré F. 2014
432 Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic
433 exposure and treatment duration on the amount of resistant enterobacteria excreted. *PLoS*
434 *Comput. Biol.* **10**, e1003840.
- 435 13. Niehus R *et al.* 2020 Quantifying antibiotic impact on within-patient dynamics of
436 extended-spectrum beta-lactamase resistance. *Elife* **9**, e49206.
- 437 14. Ruppé E *et al.* 2015 High rate of acquisition but short duration of carriage of
438 multidrug-resistant Enterobacteriaceae after travel to the tropics. *Clin. Infect. Dis.* **61**, 593–
439 600.
- 440 15. Rondinaud E, Ruppé E, Matheron S, Lucet J-C, Armand-Lefevre L, VOYAG-R study
441 group. 2020 Screening methods for intestinal carriage of multidrug-resistant Enterobacterales:
442 interest of enrichment broth. *Diagn. Microbiol. Infect. Dis.* **97**, 115079.
- 443 16. R Core Team. 2021 R: A language and environment for statistical computing.
- 444 17. Bates D, Sarkar D, Bates MD, Matrix L. 2007 The lme4 package. *R Package Version*
445 **2**, 74.
- 446 18. Therneau TM, Lumley T. 2014 Package ‘survival’. *Surviv. Anal. Publ. CRAN* **2**, 119.

- 447 19. Melnyk AH, Wong A, Kassen R. 2015 The fitness costs of antibiotic resistance
448 mutations. *Evol. Appl.* **8**, 273–283.
- 449 20. Courchamp F, Clutton-Brock T, Grenfell B. 1999 Inverse density dependence and the
450 Allee effect. *Trends Ecol. Evol.* **14**, 405–410.
- 451 21. Kaul RB, Kramer AM, Dobbs FC, Drake JM. 2016 Experimental demonstration of an
452 Allee effect in microbial populations. *Biol. Lett.* **12**, 20160070.
- 453 22. Armand-Lefèvre L *et al.* 2021 Dynamics of extended-spectrum beta-lactamase-
454 producing Enterobacterales colonization in long-term carriers following travel abroad.
455 *Microb. Genomics* **7**.
- 456 23. Leo S *et al.* 2019 The intestinal microbiota predisposes to traveler’s diarrhea and to
457 the carriage of multidrug-resistant Enterobacteriaceae after traveling to tropical regions. *Gut*
458 *Microbes* **10**, 631–641.
- 459 24. Sabuncu E, David J, Bernède-Bauduin C, Pépin S, Leroy M, Boëlle P-Y, Watier L,
460 Guillemot D. 2009 Significant reduction of antibiotic use in the community after a nationwide
461 campaign in France, 2002–2007. *PLoS Med.* **6**, e1000084.
- 462 25. Dame-Korevaar A, Kers JG, Van Der Goot J, Velkers FC, Ceccarelli D, Mevius DJ,
463 Stegeman A, Fischer EA. 2020 Competitive exclusion prevents colonization and
464 compartmentalization reduces transmission of ESBL-producing *Escherichia coli* in broilers.
465 *Front. Microbiol.* **11**.
- 466
- 467

468 Supplementary Figures


469



470

471 Figure S1: Analysis of the statistical power of a linear model with individual identity as a random effect
472 (that we used) to detect a decline in MRE with time. The details of the analysis are provided in the main
473 text (section “Density of MRE as a function of time”). 100 data sets were simulated for each rate of decline.
474 The code is provided in supplementary material (R-markdown file). Upper panel: decline inferred by the
475 linear model (dots) as a function of the true decline. Lower panel: frequency of detection of a significant
476 decline (p -value < 0.05) as a function of the simulated MRE rate of decline.

477



478
479 Figure S2: CTX-M abundance as a function of time in data from Niehus et al. [13]. A decline in CTX-M
480 abundance is detected only following C3G treatment. Joined dots: per-individual CTX-M abundance as a
481 function of day of follow up. Solid thick line: Linear model for the log₁₀ CTX-M abundance as a function
482 of the days of follow up (colored area: 95% CI).
483